CFGS
VNDA icon

Concourse Financial Group Securities’s Vanda Pharmaceuticals VNDA Stock Holding History

Concourse Financial Group Securities’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-61
Closed -$971 – 2400
2019
Q1 		$1K Buy
+61
New +$1.39K ﹤0.01% 2193

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Concourse Financial Group Securities's VNDA Position: Q2 2019 in Review

Concourse Financial Group Securities sold out of Vanda Pharmaceuticals (VNDA) in Q2 2019, closing a stake of 61 shares — an estimated $971 sold.

Concourse Financial Group Securities first reported a position in VNDA in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 164 funds tracked by Wall St. Rank hold VNDA as of Q2 2019.

  • Concourse Financial Group Securities reported no remaining Vanda Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Concourse Financial Group Securities sold 61 Vanda Pharmaceuticals shares in Q2 2019, an estimated $971.
  • Concourse Financial Group Securities first reported a position in Vanda Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Concourse Financial Group Securities's Vanda Pharmaceuticals position peaked at $1K in Q1 2019.
  • 164 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2019.

Based on Concourse Financial Group Securities's 13F filing for Q2 2019, filed 13 Aug 2019.